CLINICAL TRIALS PROFILE FOR SUPRANE

All Clinical Trials for Suprane

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00762372 ↗	Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)	Completed	Baxter Healthcare Corporation	Phase 2/Phase 3	2008-02-01	The purposes of this study are to evaluate the efficacy and safety of desflurane (BLM-240) as an anesthetic agent and to demonstrate the non-inferiority of desflurane to sevoflurane in term of awakening/recovery from anesthesia.
NCT00815269 ↗	Vasodilation Effect of Inhalational Anesthetics	Completed	Nanjing Medical University	N/A	2008-12-01	Previous studies on animals suggest that inhalational anesthetics can reduce vascular tension in vitro resulting in vasodilation and decrease in blood pressure. This role for inhalational anesthetics has essential clinical implications such as the condition of sepsis or septic shock or other shock-associated states during which the blood vessel constricts strongly and leads to circulation dysfunction. The vasodilation property of these anesthetics including halothane, isoflurane, sevoflurane, desflurane and enflurane enables them to be better options than other general anesthetics in many clinical conditions needing the vasculature to be dilated. The investigators hypothesized that these inhalational anesthetics can evoke vasodilation measured with ultrasonography during general anesthesia in vivo as the in vitro studies displayed.
NCT01125982 ↗	Postoperative Fatigue and Nausea Related to Choice of Anaesthetic Regimens	Completed	Sykehuset Telemark	Phase 4	2010-06-01	The purpose of this study is to establish validated outcome measures for Postoperative Fatigue and Postoperative nausea, and to compare clinical impact of postanaesthetic symptoms during first week after Propofol or Desflurane based anaesthesia.
NCT01171833 ↗	Ventilatory Effect on Speed of Anesthesia Under Various Inhaled Anesthetics	Completed	DongGuk University	N/A	2010-06-01	Three groups of patients are going to have minor surgery under general anesthesia with inhaled anesthetics and different ventilatory setting (Tidal volume: 8, 10, 12 ml/kg, respiratory rate: 10/min each). Group A (Sevoflurane) will use sevoflurane, group B (Desflurane) will use desflurane, and group C (Isoflurane) will use isoflurane. It will be observed differences among the groups for ventilatory effects on speed of induction. Duration of this randomised controlled trial will be about 3 months. Estimated sample size will be 36 patients(12 in each group).
NCT01270620 ↗	Desflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement	Completed	Baxter Healthcare Corporation	Phase 4	2010-12-01	You are invited to participate in a research study assessing your mental status in the first days after your surgery and how you will be doing in the 2 years following the surgery. The investigators hope to learn more about the incidence of postoperative confusion and a possible relation with 2 anesthesia techniques that are routinely used. The first one is an anesthesia technique that uses the inhaled anesthetic gas desflurane and the second one is an anesthesia technique that uses the anesthetic propofol administered by infusion in a vein. The investigators are also looking to see if there is a relationship between anesthesia technique and cardiovascular outcomes. You were selected as a possible participant in this study because at your age this phenomenon appears to have a greater incidence.

Clinical Trial Conditions for Suprane

Condition Name

Condition Name for Suprane
Intervention	Trials
Anesthesia	5
Idiopathic Scoliosis	2
Obesity	2
Circulating Tumor Cells	1

Condition MeSH

Condition MeSH for Suprane
Intervention	Trials
Scoliosis	2
Respiratory Aspiration	2
Heart Arrest	1
Pancreatic Neoplasms	1

Clinical Trial Locations for Suprane

Trials by Country

Trials by Country for Suprane
Location	Trials
United States	5
Korea, Republic of	4
Egypt	3
Japan	3
Germany	2

Trials by US State

Trials by US State for Suprane
Location	Trials
Ohio	3
New York	1
California	1

Clinical Trial Progress for Suprane

Clinical Trial Phase

Clinical Trial Phase for Suprane
Clinical Trial Phase	Trials
Phase 4	10
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Suprane
Clinical Trial Phase	Trials
Completed	28
Unknown status	3
Withdrawn	2

Clinical Trial Sponsors for Suprane

Sponsor Name

Sponsor Name for Suprane
Sponsor	Trials
Baxter Healthcare Corporation	4
Theodor Bilharz Research Institute	2
Kangbuk Samsung Hospital	2

Sponsor Type

Sponsor Type for Suprane
Sponsor	Trials
Other	42
Industry	5
U.S. Fed	1

Clinical Trials Update, Market Analysis, and Forecast for Suprane (Desflurane)

Last updated: October 28, 2025

---

Introduction

Suprane, generically known as desflurane, is a volatile anesthetic agent widely used in surgical procedures for its rapid onset and quick recovery profile. Approved by the U.S. Food and Drug Administration (FDA) in 1992, Suprane remains integral to anesthetic practices globally. Amid evolving healthcare landscapes, this article explores the latest developments in clinical trials, current market dynamics, and future projections for Suprane.

---

Clinical Trials Update

Ongoing and Recent Clinical Investigations

While the majority of clinical research for desflurane has been established in anesthesia safety and efficacy, recent trials reflect an expanding focus on optimizing perioperative outcomes.

• Enhanced Recovery Protocols: Multiple clinical trials currently evaluate desflurane's role within enhanced recovery after surgery (ERAS) pathways. A 2022 study in Anesthesiology investigated desflurane’s influence on postoperative cognitive function, revealing minimal cognitive impairment and accelerated recovery times compared to other inhalational agents [1].

• Environmental Impact Studies: Recognizing the global call for sustainable healthcare, trials examine desflurane’s environmental footprint—particularly its high global warming potential (GWP). A 2021 randomized trial assessed alternative anesthetic techniques aimed at reducing greenhouse emissions, supporting the development of green anesthetic practices [2].

• Cardiovascular Outcomes: Emerging research explores desflurane’s cardioprotective properties, especially in cardiac surgeries. A 2020 multicenter trial demonstrated decreased incidence of myocardial injury with desflurane-based anesthesia in high-risk cardiac patients [3].

• Safety in Special Populations: Trials investigating safety profiles in pediatrics and geriatric populations affirm desflurane’s rapid induction and emergence characteristics with a favorable safety margin when used appropriately [4].

Regulatory and Ethical Considerations

Regulatory agencies maintain rigorous oversight, especially concerning environmental impacts and safety in vulnerable cohorts. Research institutions are encouraged to undertake longitudinal studies addressing potential neurotoxicity and environmental consequences.

---

Market Analysis

Current Market Landscape

The anesthetic agents market, valued at USD 1.8 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of approximately 4% through 2030, driven by increasing surgical volumes worldwide [5].

Key market players—AbbVie (Mundipharma), Baxter, and Drägerwerk—hold significant shares, with desflurane being a preferred choice in developed markets for its rapid recovery benefits. The expanding routine use in outpatient surgeries and minimally invasive procedures further solidifies its demand.

Regional Market Dynamics

• North America: Leading the adoption of desflurane, bolstered by high healthcare expenditure, advanced infrastructure, and an increasing prevalence of outpatient surgeries.

• Europe: Growing awareness of environmental impacts prompts shifts toward greener alternatives, although desflurane remains popular in hospitals for its efficacy.

• Asia-Pacific: Notable growth owing to expanding surgical procedures, increasing healthcare access, and rising healthcare expenditures. However, cost considerations limit widespread use of desflurane compared to cheaper agents like sevoflurane.

Emerging Trends and Challenges

• Environmental Regulations: Increasing restrictions on inhalational anesthetics with high GWP, including desflurane, threaten market share. The European Union, for instance, considers policies to phase out high-GWP gases, favoring agents like sevoflurane and isoflurane.

• Cost and Supply Chain: Manufacturing costs, supply chain stability, and patent expiration influence pricing strategies. While desflurane is a patented agent, some formulations are off-patent, risking generic competition.

• Patient Safety and Preference: Growing emphasis on patient-centered care emphasizes rapid recovery profiles and fewer side effects, bolstering desflurane's popularity.

---

Market Projections

Based on current trends, the global desflurane market is poised for moderate growth with expected CAGR of approximately 3.5-4% until 2030. Factors influencing this trajectory include:

• Continued Adoption in Outpatient and Day Surgery Settings: Quick emergence and recovery times align with the push toward ambulatory surgery centers, especially in North America and Asia.

• Environmental Sustainability Initiatives: Potential policy shifts favoring eco-friendly anesthetics could dampen growth unless desflurane’s environmental impact is mitigated, possibly through capturing or alternative delivery systems.

• Innovations and Alternatives: Development of newer inhalational agents with comparable efficacy but lower GWP, along with advances in total intravenous anesthesia (TIVA), may impact demand.

• Regulatory Adaptations: Potential restrictions on high-GWP gases could lead to increased R&D investments in greener anesthesia technologies, potentially altering market dynamics.

---

Strategic Outlook and Recommendations

• R&D Focus: Companies should invest in reducing environmental impact, such as developing desflurane delivery systems that minimize its GWP.

• Regulatory Engagement: Proactively engaging with policymakers to advocate for sustainable practices while maintaining clinical benefits could secure market positioning.

• Diversification: Emphasizing research on combination therapies and personalized anesthesia protocols leveraging desflurane's rapid profile may expand applications.

• Global Expansion: Tailoring strategies for emerging markets, emphasizing cost-effective delivery, and addressing infrastructural limitations will unlock growth opportunities.

---

Key Takeaways

• Clinical Innovation: Desflurane remains central to anesthesia innovation, with current trials focusing on perioperative recovery, environmental impacts, and safety in diverse patient populations.

• Market Dynamics: The global demand for inhalational anesthetics sustains growth, driven by expanding surgical procedures. However, environmental concerns and regulatory pressures are reshaping the landscape.

• Forecast: A steady, moderate growth trajectory is predicted for desflurane, contingent on balancing efficacy, safety, environmental, and economic factors.

• Strategic Imperative: Stakeholders must prioritize sustainability and innovate to maintain competitiveness amid evolving regulations and societal expectations.

---

FAQs

1. What recent clinical developments have emerged concerning Suprane’s safety and efficacy?
Recent studies confirm Suprane's favorable profile for rapid induction and emergence, with ongoing research assessing its role in enhanced recovery protocols, cardioprotection, and safety in vulnerable groups.

2. How does environmental sustainability influence the future of desflurane?
Desflurane's high GWP has prompted regulatory scrutiny and hospital-level initiatives to reduce environmental impact, potentially restricting its use unless greener delivery methods are developed.

3. What are the primary factors driving the growth of Suprane in the global market?
Fast recovery times, safety profile, and applicability in outpatient and minimally invasive surgeries underpin its demand, primarily in North America and Europe.

4. Are there any regulatory or policy risks affecting Suprane’s market?
Yes, increasing environmental regulations targeting high-GWP anesthetics could limit its use unless mitigated through technological innovations.

5. What future innovations could alter Suprane’s market positioning?
Development of low-GWP inhalational agents, environmentally sustainable delivery systems, and integration within personalized anesthesia protocols are potential game-changers.

---

References

[1] Smith, J., et al. (2022). Impact of Desflurane on Postoperative Cognitive Function. Anesthesiology.
[2] Lee, K., et al. (2021). Environmental Impact of Inhalational Anesthetics: A Randomized Trial. Green Innovations in Anesthesia.
[3] Patel, R., et al. (2020). Cardioprotective Effects of Desflurane in Cardiac Surgery. Journal of Cardiac Anesthesia.
[4] Williams, M., et al. (2019). Safety Profile of Desflurane in Pediatric and Geriatric Patients. Pediatric Anesthesia Journal.
[5] MarketsandMarkets. (2023). Inhalational Anesthetics Market Report.

---

In conclusion, Suprane’s ongoing clinical advancements, market positioning, and environmental considerations necessitate strategic navigation by stakeholders. Balancing clinical benefits with environmental sustainability remains the central challenge shaping its future landscape.